BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 29396434)

  • 41. C5b-9 assembly: average binding of one C9 molecule to C5b-8 without poly-C9 formation generates a stable transmembrane pore.
    Bhakdi S; Tranum-Jensen J
    J Immunol; 1986 Apr; 136(8):2999-3005. PubMed ID: 3958488
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers.
    Meri S; Morgan BP; Davies A; Daniels RH; Olavesen MG; Waldmann H; Lachmann PJ
    Immunology; 1990 Sep; 71(1):1-9. PubMed ID: 1698710
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery.
    Pratt WB; Toft DO
    Exp Biol Med (Maywood); 2003 Feb; 228(2):111-33. PubMed ID: 12563018
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Complement lysis of U937, a nucleated mammalian cell line in the absence of C9: effect of C9 on C5b-8 mediated cell lysis.
    Morgan BP; Imagawa DK; Dankert JR; Ramm LE
    J Immunol; 1986 May; 136(9):3402-6. PubMed ID: 3514758
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Elevated levels of mitochondrial mortalin and cytosolic HSP70 in blood as risk factors in patients with colorectal cancer.
    Rozenberg P; Kocsis J; Saar M; Prohászka Z; Füst G; Fishelson Z
    Int J Cancer; 2013 Jul; 133(2):514-8. PubMed ID: 23319326
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Target deletion of complement component 9 attenuates antibody-mediated hemolysis and lipopolysaccharide (LPS)-induced acute shock in mice.
    Fu X; Ju J; Lin Z; Xiao W; Li X; Zhuang B; Zhang T; Ma X; Li X; Ma C; Su W; Wang Y; Qin X; Liang S
    Sci Rep; 2016 Jul; 6():30239. PubMed ID: 27444648
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhibition of Hsp90 function delays and impairs recovery from heat shock.
    Duncan RF
    FEBS J; 2005 Oct; 272(20):5244-56. PubMed ID: 16218955
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Additive viability-loss following hsp70/hsc70 double interference and Hsp90 inhibition in two breast cancer cell lines.
    Håvik B; Bramham CR
    Oncol Rep; 2007 Jun; 17(6):1501-10. PubMed ID: 17487411
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cooperative action of Hsp70, Hsp90, and DnaJ proteins in protein renaturation.
    Schumacher RJ; Hansen WJ; Freeman BC; Alnemri E; Litwack G; Toft DO
    Biochemistry; 1996 Nov; 35(47):14889-98. PubMed ID: 8942653
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Kinetics of polymerization of a fluoresceinated derivative of complement protein C9 by the membrane-bound complex of complement proteins C5b-8.
    Sims PJ; Wiedmer T
    Biochemistry; 1984 Jul; 23(14):3260-7. PubMed ID: 6432040
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Several epitopes on native human complement C9 are involved in interaction with the C5b-8 complex and other C9 molecules.
    Kontermann R; Deppisch R; Rauterberg EW
    Eur J Immunol; 1990 Mar; 20(3):623-8. PubMed ID: 1690659
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Regulating the cytoprotective response in cancer cells using simultaneous inhibition of Hsp90 and Hsp70.
    Wang Y; McAlpine SR
    Org Biomol Chem; 2015 Feb; 13(7):2108-16. PubMed ID: 25526223
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Transfer of preformed terminal C5b-9 complement complexes into the outer membrane of viable gram-negative bacteria: effect on viability and integrity.
    Tomlinson S; Taylor PW; Luzio JP
    Biochemistry; 1990 Feb; 29(7):1852-60. PubMed ID: 2184889
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents.
    Miyata Y
    Curr Pharm Des; 2005; 11(9):1131-8. PubMed ID: 15853661
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bacterial killing and inhibition of inner membrane activity by C5b-9 complexes as a function of the sequential addition of C9 to C5b-8 sites.
    MacKay SL; Dankert JR
    J Immunol; 1990 Nov; 145(10):3367-71. PubMed ID: 2230122
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MUC1 oncoprotein is targeted to mitochondria by heregulin-induced activation of c-Src and the molecular chaperone HSP90.
    Ren J; Bharti A; Raina D; Chen W; Ahmad R; Kufe D
    Oncogene; 2006 Jan; 25(1):20-31. PubMed ID: 16158055
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Modulation of Hsf1 activity by novobiocin and geldanamycin.
    Conde R; Belak ZR; Nair M; O'Carroll RF; Ovsenek N
    Biochem Cell Biol; 2009 Dec; 87(6):845-51. PubMed ID: 19935870
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interaction of the Hsp90 cochaperone cyclophilin 40 with Hsc70.
    Carrello A; Allan RK; Morgan SL; Owen BA; Mok D; Ward BK; Minchin RF; Toft DO; Ratajczak T
    Cell Stress Chaperones; 2004; 9(2):167-81. PubMed ID: 15497503
    [TBL] [Abstract][Full Text] [Related]  

  • 59. hsp70 interacting protein Hip does not affect glucocorticoid receptor folding by the hsp90-based chaperone machinery except to oppose the effect of BAG-1.
    Kanelakis KC; Murphy PJ; Galigniana MD; Morishima Y; Takayama S; Reed JC; Toft DO; Pratt WB
    Biochemistry; 2000 Nov; 39(46):14314-21. PubMed ID: 11087380
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Down-regulation of p210(bcr/abl) by curcumin involves disrupting molecular chaperone functions of Hsp90.
    Wu LX; Xu JH; Huang XW; Zhang KZ; Wen CX; Chen YZ
    Acta Pharmacol Sin; 2006 Jun; 27(6):694-9. PubMed ID: 16723087
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.